Laurion Capital Management LP bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,200 shares of the medical instruments supplier’s stock, valued at approximately $220,000.

Other hedge funds have also modified their holdings of the company. Cantillon Capital Management LLC raised its stake in shares of Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock valued at $246,622,000 after buying an additional 312,926 shares during the last quarter. JPMorgan Chase & Co. increased its position in Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Prudential Financial Inc. increased its position in Becton, Dickinson and by 34.0% in the first quarter. Prudential Financial Inc. now owns 930,445 shares of the medical instruments supplier’s stock valued at $170,681,000 after buying an additional 236,280 shares during the period. Montag & Caldwell LLC purchased a new position in Becton, Dickinson and during the first quarter valued at $34,713,000. Finally, Private Advisor Group LLC increased its position in shares of Becton, Dickinson and by 2,402.0% in the first quarter. Private Advisor Group LLC now owns 184,972 shares of the medical instruments supplier’s stock worth $10,190,000 after buying an additional 177,579 shares during the last quarter. 75.57% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company (NYSE BDX) traded down 0.81% during mid-day trading on Friday, hitting $197.69. The stock had a trading volume of 989,225 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The company has a 50-day moving average of $199.72 and a 200-day moving average of $188.69. The firm has a market cap of $44.99 billion, a PE ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 earnings per share. Analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

ILLEGAL ACTIVITY NOTICE: “Laurion Capital Management LP Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/laurion-capital-management-lp-invests-220000-in-becton-dickinson-and-company-nysebdx-updated-updated-updated.html.

A number of equities research analysts have commented on the company. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $186.00 to $200.00 in a research note on Monday, April 24th. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has a consensus rating of “Buy” and an average target price of $195.79.

In related news, insider Nabil Shabshab sold 6,149 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the sale, the insider now owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. In the last three months, insiders sold 57,631 shares of company stock worth $11,112,178. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.